Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.34 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12283793 | 1.00 | AKR1C3 (0.43) | AKR1C3AKR1C2POLBALDH1A1MAPT | |
| SCHEMBL12283890 | 0.80 | ALDH1A1 (0.39) | AKR1C3AKR1C2POLBALDH1A1MAPT | |
| SCHEMBL2319362 | 0.80 | ALDH1A1 (0.39) | AKR1C3AKR1C2POLBALDH1A1MAPT | |
| SCHEMBL2318382 | 0.79 | POLB (0.42) | POLBALDH1A1MAPTKMT2ACYP2D6 | |
| SCHEMBL17872620 | 0.78 | POLB (0.43) | AKR1C3AKR1C2POLBALDH1A1KMT2A | |
| SCHEMBL17872617 | 0.78 | POLB (0.43) | AKR1C3AKR1C2POLBALDH1A1KMT2A | |
| SCHEMBL24667087 | 0.78 | TDP1 (0.36) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL22052762 | 0.78 | TDP1 (0.36) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL22052763 | 0.78 | TDP1 (0.36) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL21739121 | 0.78 | TDP1 (0.36) | AKR1C3AKR1C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | AKR1C3 872/4885AKR1C2 989/4885POLB 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.